Autologous

Special Edition: The Future of Continuous BioProcessing

Erbi Biosystems’ platform is designed to support continuous processing, and startup flags its potential to transform CAR-T and other autologous therapies

02-Dec-2020 By Jane Byrne

Erbi Biosystems recently raised US$3.8m in a round led by Jaguar Biotech; the funds will allow the company to expand its platform of microfluidic bioprocess and bioreactor equipment, which is said to enable ultra-high cell density and continuous processing.

Consolidation continues as Catalent lays down $330m for MaSTherCell

05-Feb-2020 By Ben Hargreaves

Catalent provides another example of the trend by bigger CDMO to snatch up smaller cell and gene therapy specialists.